Filtered By:
Specialty: Endocrinology
Drug: Insulin

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 211 results found since Jan 2013.

Comparative Cardiovascular Safety of Glucagon‐Like Peptide‐1 Receptor Agonists versus Other Antidiabetic Drugs in Routine Care: a Cohort Study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RA versus other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to rule out large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - March 23, 2016 Category: Endocrinology Authors: Elisabetta Patorno, Brendan M. Everett, Allison B. Goldfine, Robert J. Glynn, Jun Liu, Chandrasekar Gopalakrishnan, Seoyoung C. Kim Tags: Original Article Source Type: research

Androgen receptor (AR) in cardiovascular diseases
Cardiovascular diseases (CVDs) are still the highest leading cause of death worldwide. Several risk factors have been linked to CVDs, including smoking, diabetes, hyperlipidemia, and gender among others. Sex hormones, especially the androgen and its receptor, androgen receptor (AR), have been linked to many diseases with a clear gender difference. Here, we summarize the effects of androgen/AR on CVDs, including hypertension, stroke, atherosclerosis, abdominal aortic aneurysm (AAA), myocardial hypertrophy, and heart failure, as well as the metabolic syndrome/diabetes and their impacts on CVDs. Androgen/AR signaling exacerba...
Source: Journal of Endocrinology - April 28, 2016 Category: Endocrinology Authors: Huang, C.-K., Lee, S. O., Chang, E., Pang, H., Chang, C. Tags: Review Source Type: research

The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone
Source: Journal of Diabetes - June 7, 2016 Category: Endocrinology Authors: Silvio E. Inzucchi, Karen L. Furie Tags: Commentary Source Type: research

Cardiovascular Safety of Glucose‐Lowering Agents as Add‐on Medication to Metformin Treatment in Type 2 Diabetes:Report from the Swedish National Diabetes Register (NDR)
Conclusions: This nationwide observational study showed that second‐line treatment with TZD and DPP‐4i as add‐on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Source: Diabetes, Obesity and Metabolism - May 31, 2016 Category: Endocrinology Authors: Nils Ekström, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir Tags: ORIGINAL ARTICLE Source Type: research

Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Abstract Sodium glucose cotransporter 2 (SGLT2) inhibitors have a unique mechanism of action leading to excretion of glucose in the urine and subsequent lowering of plasma glucose. This mechanism is independent of β-cell function; thus, these agents are effective treatment for type 2 diabetes mellitus (T2DM) at theoretically any disease stage. This class should not confer an additional risk of hypoglycemia (unless combined with insulin or an insulin secretagogue) and has the potential to be combined with other classes of glucose-lowering agents. Empagliflozin is one of three currently approved SGLT2 inhibitors in...
Source: Current Diabetes Reviews - June 12, 2016 Category: Endocrinology Authors: Levine MJ Tags: Curr Diabetes Rev Source Type: research

Cardiovascular safety of glucose ‐lowering agents as add‐on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register
ConclusionsThis nationwide observational study showed that second‐line treatment with TZD and DPP‐4 inhibitor as add‐on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Source: Diabetes, Obesity and Metabolism - July 18, 2016 Category: Endocrinology Authors: Nils Ekstr öm, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir Tags: ORIGINAL ARTICLE Source Type: research

Comparative cardiovascular safety of glucagon ‐like peptide‐1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RAs with other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to exclude large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - May 1, 2016 Category: Endocrinology Authors: E. Patorno, B. M. Everett, A. B. Goldfine, R. J. Glynn, J. Liu, C. Gopalakrishnan, S. C. Kim Tags: ORIGINAL ARTICLE Source Type: research

Associations of 25-hydroxyvitamin D with markers of inflammation, insulin resistance and obesity in black and white community-dwelling adults
Conclusions Lower 25(OH)D concentrations are associated with disturbances in metabolic health in both blacks and whites. Whether correcting vitamin D deficiency could offer a beneficial therapy for disease prevention requires further study.
Source: Journal of Clinical and Translational Endocrinology - July 27, 2016 Category: Endocrinology Source Type: research

TNP N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway
Conclusion We demonstrate that pharmacologic inhibition of the inositol pyrophosphate pathway has strong therapeutic potential in obesity, T2D, and other metabolic diseases.
Source: Molecular Metabolism - August 20, 2016 Category: Endocrinology Source Type: research

Obesity: single house for many evils.
Authors: Kumar A, Nayak BP, Kumar A Abstract World Health Organization (WHO) considers obesity as one of the fastest growing metabolic disorders other than diabetes. It is a complex interplay of lifestyle and associated genes. Obesity has been considered as a disease with multiple targets and very often compared in this sense with its sibling disease type 2 diabetes. The disease is pathology of the adipocytes and develops as a result of hypertrophy and hyperplasia of these cells, former being the major concern but its effects could be seen on various organs in the form of cardio-vascular disease, stroke, cancer, di...
Source: Minerva Endocrinologica - September 9, 2016 Category: Endocrinology Tags: Minerva Endocrinol Source Type: research

IRS proteins and diabetic complications
AbstractIRS proteins are cellular adaptor molecules that mediate many of the key metabolic actions of insulin. When tyrosine is phosphorylated by the activated insulin receptor, IRS proteins recruit downstream effectors, such as phosphoinositide 3-kinase and mitogen-activated protein kinase, in order to elicit cellular responses such as glucose uptake, lipid metabolism and cell proliferation. There are two main IRS proteins in humans (IRS1 and IRS2), both of which are widely expressed. Given their central role in the insulin signalling pathway, it is not surprising that male mice lackingIrs1 orIrs2 present with elevated bl...
Source: Diabetologia - September 30, 2016 Category: Endocrinology Source Type: research

ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients
Conclusions/interpretationIn patients with type 2 diabetes, serum ANGPTL2 concentrations were independently associated with death and MACE. Therefore, ANGPTL2 is a promising candidate biomarker for improving risk stratification in type 2 diabetes patients, and may prove to be a valuable therapeutic target.
Source: Diabetologia - September 30, 2016 Category: Endocrinology Source Type: research

Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
ConclusionsThese data provide evidence that treatment with liraglutide is associated with improvement of cardiac function and functional capacity in failing post-ischemic type-2 diabetes mellitus patients.
Source: Endocrine - November 8, 2016 Category: Endocrinology Source Type: research

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
AbstractEmpagliflozin is an oral treatment for type 2 diabetes mellitus (T2DM), one of the leading causes of death in the US and around the world. Recently, the EMPA-REG OUTCOME study has shown that empagliflozin added to standard of care treatment reduced the risk of cardiovascular (CV) events in patients with T2DM who were also at increased CV risk. The risk of major adverse CV events (MACE: first occurrence of CV death, non-fatal myocardial infarction, or non-fatal stroke) was reduced by 14% relative to placebo (HR 0.86; 95.02% CI: 0.74 –0.99;P = 0.04 for superiority). The risk of CV death was reduced by 38% relativ...
Source: Diabetes Therapy - November 10, 2016 Category: Endocrinology Source Type: research

Cardiovascular events and all ‐cause mortality associated with sulfonylureas compared to other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data
ConclusionThis meta‐analysis shows an association between sulfonylurea therapy and a higher risk of major cardiovascular disease‐related events compared to other antihyperglycaemic drugs. Results of ongoing RCTs, which should be available in 2018, will provide definitive results on the risk of cardiovascular events and all‐cause mortality associated with sulfonylureas versus other antihyperglycaemic drugs.
Source: Diabetes, Obesity and Metabolism - October 31, 2016 Category: Endocrinology Authors: Steve Bain, Eric Druyts, Chakrapani Balijepalli, Carl A Baxter, Craig Currie, Romita Das, Richard Donnelly, Kamlesh Khunti, Haya Langerman, Paul Leigh, Gaye Siliman, Kristian Thorlund, Kabirraaj Toor, Jiten Vora, Edward J Mills Tags: Original Article Source Type: research